Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 9/2018

22.06.2018 | Original Article – Clinical Oncology

Liver metastases from colorectal cancer: propensity score-based comparison of stereotactic body radiation therapy vs. microwave ablation

verfasst von: Ciro Franzese, Tiziana Comito, Elena Clerici, Lucia Di Brina, Stefano Tomatis, Pierina Navarria, Giacomo Reggiori, Luca Viganò, Dario Poretti, Vittorio Pedicini, Guido Torzilli, Luigi Solbiati, Marta Scorsetti

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The study aim was to compare the disease control in two groups of patients affected by liver metastases from CRC treated with microwave ablation (MWA) or stereotactic body radiation therapy (SBRT).

Methods

We extracted data of patients treated between 2009 and 2016. Inclusion criteria were: (1) maximum diameter of the liver lesions less than 4 cm; (2) no more than three liver lesions; (3) no evidence of progressive or untreated gross disease outside the liver; (4) adequate liver function; (5) no concurrent chemotherapy; (6) minimum age of 18. Tumour response was classified according to EORTC-RECIST criteria. Aim of the present study was to evaluate freedom from local progression (FFLP). To reduce indication bias, an inverse probability of treatment weighting was used to estimate treatment effect.

Results

A total of 135 patients with 214 lesions were included in the analysis. Median follow-up time was 24.5 months (range 2.4–95.8). The 1-year freedom from local progression (FFLP) was 88% (95%CI 80–92). In the SBRT group, FFLP was statistically longer than MWA group (p = 0.0214); the 1-year FFLP was 91% (95% CI 81–95) in SBRT group and 84% (95% CI 0.72–0.91) in MWA group. Patients treated with SBRT showed a reduce risk of local relapse compared to MWA (adjusted HR 0.31; 95%CI 0.13–0.70, p = 0.005). As expected, analogous result obtained in the inverse probability weighting analysis (HR 0.38; 95%CI 0.18–0.80; p = 0.011).

Conclusion

In conclusion, there seems to be an advantage of SBRT compared to MWA in treating CRC liver metastases, particularly for lesions bigger than 30 mm
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Hoyer M, Roed H, Hansen AT et al (2006) Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 45:823–830CrossRefPubMed Hoyer M, Roed H, Hansen AT et al (2006) Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 45:823–830CrossRefPubMed
Zurück zum Zitat Kim YS, Lee WJ, Rhim H, Lim HK, Choi DLJ (2010) The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (> 2 and < 5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. AJR Am J Roentgenol 195:758–765CrossRefPubMed Kim YS, Lee WJ, Rhim H, Lim HK, Choi DLJ (2010) The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (> 2 and < 5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. AJR Am J Roentgenol 195:758–765CrossRefPubMed
Zurück zum Zitat Lee M, Kim J, Dinniwell R et al (2009) Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 27:1585–1591CrossRefPubMed Lee M, Kim J, Dinniwell R et al (2009) Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 27:1585–1591CrossRefPubMed
Zurück zum Zitat Solbiati L, Ahmed M, Cova L, Ierace T, Brioschi MGS (2012) Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology 265:958–968CrossRefPubMed Solbiati L, Ahmed M, Cova L, Ierace T, Brioschi MGS (2012) Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology 265:958–968CrossRefPubMed
Zurück zum Zitat Stewart BW, Kleihues P (2003) Eds. Colorectal cancer. World cancer report. IARC Press, Lyon, 163–166 Stewart BW, Kleihues P (2003) Eds. Colorectal cancer. World cancer report. IARC Press, Lyon, 163–166
Zurück zum Zitat Timmerman L, Papiez L, McGarry R, Likes L (2003) Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell. Chest 124(5):1946–1955CrossRefPubMed Timmerman L, Papiez L, McGarry R, Likes L (2003) Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell. Chest 124(5):1946–1955CrossRefPubMed
Zurück zum Zitat van der Pool AE, Romero AM, Wunderink W et al (2010) Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg 97:377–382CrossRefPubMed van der Pool AE, Romero AM, Wunderink W et al (2010) Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg 97:377–382CrossRefPubMed
Zurück zum Zitat Wang X, Sofocleous CT, Erinjeri JP, Petre EN et al (2013) Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases. Cardiovasc Intervent Radiol 36(1):166–175CrossRefPubMed Wang X, Sofocleous CT, Erinjeri JP, Petre EN et al (2013) Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases. Cardiovasc Intervent Radiol 36(1):166–175CrossRefPubMed
Metadaten
Titel
Liver metastases from colorectal cancer: propensity score-based comparison of stereotactic body radiation therapy vs. microwave ablation
verfasst von
Ciro Franzese
Tiziana Comito
Elena Clerici
Lucia Di Brina
Stefano Tomatis
Pierina Navarria
Giacomo Reggiori
Luca Viganò
Dario Poretti
Vittorio Pedicini
Guido Torzilli
Luigi Solbiati
Marta Scorsetti
Publikationsdatum
22.06.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 9/2018
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-018-2692-7

Weitere Artikel der Ausgabe 9/2018

Journal of Cancer Research and Clinical Oncology 9/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.